Transcriptomic heterogeneity of androgen receptor (AR) activity defines a de novo low AR-active subclass in treatment na ïve primary prostate cancer.

CONCLUSIONS: Leveraging large-scale transcriptomic data allowed the identification of an aggressive subtype of treatment-naïve primary prostate cancer that harbors molecular features more analogous to mCRPC. This suggests that a pre-existing subgroup of patients may have tumors that are predisposed to fail multiple current standard of care therapies and warrant dedicated therapeutic investigation.
PMID: 31515456 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - September 11, 2019 Category: Cancer & Oncology Authors: Spratt DE, Alshalalfa M, Fishbane N, Weiner AB, Mehra R, Mahal BA, Lehrer J, Liu Y, Zhao SG, Speers C, Morgan TM, Dicker AP, Freedland SJ, Karnes RJ, Weinmann S, Davicioni E, Ross AE, Den RB, Nguyen PL, Feng FY, Lotan TL, Chinnaiyan AM, Schaeffer EM Tags: Clin Cancer Res Source Type: research